CN116004475A - Lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof - Google Patents
Lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof Download PDFInfo
- Publication number
- CN116004475A CN116004475A CN202310119349.6A CN202310119349A CN116004475A CN 116004475 A CN116004475 A CN 116004475A CN 202310119349 A CN202310119349 A CN 202310119349A CN 116004475 A CN116004475 A CN 116004475A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- milk
- parts
- cold
- assisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 56
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 56
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 56
- 210000002784 stomach Anatomy 0.000 title claims abstract description 34
- 235000013336 milk Nutrition 0.000 claims description 21
- 239000008267 milk Substances 0.000 claims description 21
- 210000004080 milk Anatomy 0.000 claims description 21
- 235000015140 cultured milk Nutrition 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 241000219173 Carica Species 0.000 claims description 14
- 235000009467 Carica papaya Nutrition 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 12
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 11
- 108010046377 Whey Proteins Proteins 0.000 claims description 11
- 102000007544 Whey Proteins Human genes 0.000 claims description 11
- 229940041514 candida albicans extract Drugs 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 11
- 239000001814 pectin Substances 0.000 claims description 11
- 235000010987 pectin Nutrition 0.000 claims description 11
- 229920001277 pectin Polymers 0.000 claims description 11
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 11
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 11
- 235000021119 whey protein Nutrition 0.000 claims description 11
- 239000012138 yeast extract Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 235000020603 homogenised milk Nutrition 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 235000021552 granulated sugar Nutrition 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000009629 microbiological culture Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 230000037406 food intake Effects 0.000 abstract description 3
- 230000007413 intestinal health Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 8
- 239000003833 bile salt Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940093761 bile salts Drugs 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof, and particularly adopts lactobacillus plantarum LP23 (Lactobacillus plantarum) to prepare a product for preventing and assisting in treating stomach deficiency-cold, which can maintain gastrointestinal flora balance, inhibit pathogenic bacteria colonization, reduce inflammatory reaction and promote intestinal health and stomach through exogenous ingestion, and is a natural and safe product suitable for various physique administrations.
Description
Technical Field
The invention relates to lactobacillus plantarum, in particular to lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof. Belongs to the technical field of biological medicine processing.
Background
Stomach deficiency-cold is one of the common digestive tract diseases in modern life, is different from acute gastritis, is gastric mucosa inflammation pathological change or atrophic pathological change mainly infiltrated by lymphocyte and plasma cells, and has the characteristics of repeated attack and longer disease course. The etiology of stomach deficiency-cold is related to helicobacter pylori infection, autoimmune system, eating habit, age, etc. Clinical verification shows that the pathogenesis of stomach deficiency-cold is generally from superficial gastritis, atrophic gastritis, intestinal metaplasia or atypical hyperplasia, gastric cancer, the incidence rate is high at the first place of various stomach diseases, and the higher the age, the higher the incidence rate of stomach deficiency-cold.
The clinic treatment mode for the deficiency-cold in the stomach is mainly tetrad therapy: proton pump inhibitors inhibit gastric acid secretion thereby alleviating irritation to the gastric mucosa; metronidazole and amoxicillin are used for eliminating inflammation and helicobacter pylori; the gastric mucosa is protected by bismuth agent. However, the tetrad therapy is antibiotic therapy, and the later stage may cause gastrointestinal flora disorder, repeated illness and symptom aggravation. Related researches show that the combination of the probiotic therapy in the treatment of patients with stomach deficiency-cold can maintain the balance of gastrointestinal flora, stabilize the curative effect and accelerate the elimination of inflammatory response.
The probiotics are living bacteria beneficial to the micro-ecological balance and physiological health of the intestinal canal of a host, and lactic acid bacteria and bifidobacteria are widely used. Animal experiments show that the immunoregulation effect of probiotics is mainly to reduce the inflammatory response of stomach deficiency-cold by influencing the balance of pro-inflammatory factors and anti-inflammatory factors. Although the number of stomach microorganisms is small compared with that of intestinal microorganisms, the stomach microorganisms can participate in gastric mucosa protection and play an important role in related stomach lesions. Therefore, by exogenously taking lactobacillus, the effects of preventing and assisting in treating stomach deficiency-cold can be achieved by maintaining gastrointestinal flora balance, inhibiting pathogenic bacteria colonization and reducing inflammatory reaction.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof. The lactobacillus plantarum can maintain the balance of gastrointestinal flora through exogenous ingestion, inhibit the colonization of pathogenic bacteria, reduce inflammatory reaction and promote the health of intestinal tracts and stomach, and is a natural, safe and suitable product for taking with various different constitutions.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
1. lactobacillus plantarum LP23 (also called Lactobacillus plantarum LP 23) for preventing and assisting in treating stomach deficiency-cold, which has been preserved in China general microbiological culture Collection center at 8-month 22 of 2022 with a preservation address of North Chen West Lu No.1, 3 in the Korean region of Beijing city and a preservation number of CGMCC No.25571.
( And (3) injection: the "Commission Wei Jian" requirements for update of the "food-available strain List" and "infant food-available strain List" (2022, 4) ", were adjusted )
The 16SrDNA sequence of the lactobacillus plantarum is as follows:
GCTCAGGACGAACGCTGGCGGCGTGCCTAATACATGCAAGTCGAACGAACTCT
GGTATTGATTGGTGCTTGCATCATGATTTACATTTGAGTGAGTGGCGAACTGGTGAG
TAACACGTGGGAAACCTGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAA
TACCGCATAACAACTTGGACCGCATGGTCCGAGCTTGAAAGATGGCTTCGGCTATCA
CTTTTGGATGGTCCCGCGGCGTATTAGCTAGATGGTGGGGTAACGGCTCACCATGGC
AATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGC
CCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGA
TGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAACTCTGTTGTTAA
AGAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGC
CACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCG
GATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCTT
CGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGAC
AGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGG
CGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGTATGGGTAGCAA
ACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAATGCTAAGTGTTGGA
GGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTAC
GGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGC
ATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATACTATGCA
AATCTAAGAGATTAGACGTTCCCTTCGGGGACATGGATACAGGTGGTGCATGGTTGT
CGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATT
ATCAGTTGCCAGCATTAAGTTGGGCACTCTGGTGAGACTGCCGGTGACAAACCGGA
GGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGT
GCTACAATGGATGGTACAACGAGTTGCGAACTCGCGAGAGTAAGCTAATCTCTTAA
AGCCATTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCT
AGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGC
CCGTCACACCATGAGAGTTTGTAACACCCAAAGTCGGTGGGGTAACCTTTTAGGAAC
CAGCCGCCTAAGGTGGGACAGATGATTAGGGTGAAGTCGTAACAAGGTAGCCGTAG
GAGAACCTGC, as shown in SEQ ID NO. 1.
2. The application of the lactobacillus plantarum in preparing health-care food or medicine for preventing and assisting in treating stomach deficiency-cold.
3. A health food or medicine for preventing and adjuvant treating stomach deficiency cold comprises the lactobacillus plantarum.
4. A fruit granule flavored fermented milk comprising the aforementioned lactobacillus plantarum.
Preferably, the fruit granule flavored fermented milk is prepared by mixing the following components in parts by weight: 70-75 parts of pure milk, 5-10 parts of papaya pulp, 5-10 parts of oatmeal, 6-8 parts of white granulated sugar, 1-2 parts of whey protein powder, 1-2 parts of yeast extract, 231-2 parts of lactobacillus plantarum LP, 0.2-0.4 part of propylene glycol alginate and 0.05-0.15 part of pectin, wherein the viable count of lactobacillus plantarum LP23 is 1.0X10 8 CFU/ml。
5. The preparation method of the fruit granule flavored fermented milk comprises the following specific steps:
s1: firstly, heating the formula amount of pure milk to 40 ℃, then uniformly mixing the formula amount of white granulated sugar, whey protein powder, yeast extract, propylene glycol alginate and pectin, adding the mixture, stirring at a high speed, heating to 75 ℃, and stirring for 5 minutes to obtain premixed milk;
s2: cooling the premixed milk in the step S1 to about 60 ℃, homogenizing for 10 minutes under 20MPa to obtain homogenized milk;
s3: sterilizing the homogenized milk in the step S2 at 88-92 ℃ for 10 minutes, cooling to 38-42 ℃ and inoculating lactobacillus plantarum LP23, and then fermenting for 12 hours at 35 ℃ to obtain fermented milk;
s4: after fermentation, uniformly mixing the papaya pulp, the oat flakes and the fermented milk according to the formula, filling and refrigerating.
Preferably, in the step S1, the stirring speed of high-speed stirring is 6000-10000 r/min.
The invention has the beneficial effects that:
the invention adopts lactobacillus plantarum LP23 (Lactobacillus plantarum) to prepare the product for preventing and assisting in treating stomach deficiency-cold, maintains the balance of gastrointestinal tract flora through exogenous ingestion, inhibits the colonization of pathogenic bacteria, reduces inflammatory reaction, promotes the health of intestinal tracts and stomach, is a product which is natural and safe and is suitable for being taken in various different physique, and greatly expands the application field of probiotics.
The invention also prepares the fruit grain flavor fermented milk by taking pure milk, papaya pulp, oatmeal, white granulated sugar, whey protein powder, yeast extract, lactobacillus plantarum LP23, propylene glycol alginate, pectin and the like as raw materials.
Wherein, the papaya is a tropical fruit and has medicinal value, and the papaya has sweet and slightly cold taste, has the effects of strengthening spleen, resolving food stagnation, promoting digestion, invigorating stomach and the like, and is mainly used for treating symptoms such as stomachache, dyspepsia and the like.
Oat can promote gastrointestinal motility, has the effects of nourishing stomach and strengthening spleen, and simultaneously contains abundant vitamins, fat, protein and various minerals required by human bodies.
The invention can be used for preventing and assisting in treating stomach deficiency-cold through the synergistic effect of lactobacillus plantarum LP23, papaya, oat and the like.
Drawings
FIG. 1 dynamic change of body weight of rats of different groups;
FIG. 2 shows the change of inflammatory factors in gastric mucosal tissue of rats of different groups, wherein A is IL-1 beta and B is IL-17.
Preservation information
Classification naming: lactobacillus plantarum LP23
Latin Wen Xueming: lactobacillus plantarum
Preservation unit name: china general microbiological culture Collection center (China general microbiological culture collection center)
Deposit unit address: beijing city, chaoyang area, north Chenxi Lu No.1 and 3
Preservation date: 2022, 8, 22 days
Preservation number: CGMCCNO.25571
Detailed Description
The present invention will be further illustrated by the following examples, which are given by way of illustration only and are not intended to be limiting.
MRS Medium preparation
The specific components of MRS culture medium are as follows:
adding the above components into 1000mL distilled water, heating for dissolving, adjusting pH to 6.2, subpackaging, and autoclaving at 121deg.C for 18 min.
Lactobacillus plantarum LP23 isolated and extracted from Taiwan pickle
The separation method comprises the following steps: preparing Taiwan pickle juice into 10 by ten times dilution method -4 ～10 -6 Sample gradient, 1mL of diluent is prepared to prepare a flat plate by a mixed bacteria method, and the flat plate is cultured in an incubator at 30 ℃ for 48 hours. Single colony with typical lactobacillus characteristic is selected, streaked and separated on a plate, repeatedly purified, transferred to an MRS inclined plane, marked and stored at 4 ℃ for standby.
The characteristics of lactobacillus plantarum LP23 obtained by the above method are as follows: gram-positive, spore-free, motile, facultative anaerobic bacteria have a variety of morphological features, including single, paired, or short chain.
Lactobacillus plantarum LP23 gastric acid tolerance experiment
PBS buffer solution with pH value of 7.4 is prepared as a base, the pH value is adjusted to 3.0 by hydrochloric acid, sterilization is carried out for 15min at 121 ℃, lactobacillus plantarum LP23 is inoculated according to the inoculation amount of 4 percent, and sampling is carried out for measuring the number of living bacteria after 0, 1h and 2h respectively under the anaerobic condition at 30 ℃. The measurement results are shown in Table 1.
TABLE 1 gastric acid resistance test
| Time of action/(h) | 0 | 1 | 2 |
| Viable count/(LogCFU/mL) | 9.15 | 8.81 | 8.72 |
As shown in Table 1, after the Lactobacillus plantarum LP23 is treated for 2 hours, the logarithmic value of the residual viable count is 8.72, the survival rate can reach 90%, which indicates that the strain has stronger gastric acid resistance and can smoothly pass through gastric acid environment to reach the intestinal tract.
Lactobacillus plantarum LP23 bile salt tolerance experiment
Bile salts with mass concentration of 0.1%, 0.2% and 0.3% are respectively added into an MRS culture medium, lactobacillus plantarum LP23 is inoculated into the MRS culture medium according to the volume inoculation amount of 4%, and the MRS culture medium without the bile salts is taken as a blank control group. After culturing for 24 hours at a constant temperature of 30 ℃, sampling is performed to determine the number of viable bacteria, and the determination results are shown in Table 2.
TABLE 2 bile salt resistance experiments
| Group of | Control group | 0.1％ | 0.2％ | 0.3％ |
| Viable count/(LogCFU/mL) | 9.86 | 9.26 | 8.85 | 8.23 |
Table 2 shows that Lactobacillus plantarum LP23 is tolerant to 3 different concentrations of bile salts, and when the mass concentration of bile salts reaches 0.3% compared to the blank, the growth of the strain is inhibited, but the inhibition is not obvious, indicating that Lactobacillus plantarum LP23 has a stronger bile salt tolerance.
Example 1:
the formula is as follows: 72.65kg of pure milk, 10kg of papaya pulp, 5kg of oatmeal, 8kg of white granulated sugar, 1kg of whey protein powder, 1.5kg of yeast extract, 231.5kg of lactobacillus plantarum, 0.3kg of propylene glycol alginate and 0.05kg of pectin.
The specific manufacturing process comprises the following steps:
s1: heating pure milk to 40deg.C, mixing white sugar, whey protein powder, yeast extract, propylene glycol alginate and pectin, adding, stirring at high speed (6000 r/min), heating to 75deg.C, and stirring for 5min to obtain premixed milk;
s2: cooling the premixed milk in the step S1 to about 60 ℃, homogenizing for 10min under 20MPa to obtain homogenized milk;
s3: sterilizing the homogenized milk in S2 at 88 ℃ for 10min, cooling to 38 ℃ and inoculating lactobacillus plantarum LP23, and fermenting at 35 ℃ for 12h;
s4: after fermentation, the treated papaya pulp and oat flakes are uniformly mixed with the fermented milk, and the mixture is filled and refrigerated.
Example 2:
the formula is as follows: 75kg of pure milk, 5kg of papaya pulp, 8.2kg of oatmeal, 6kg of white granulated sugar, 1.5kg of whey protein powder, 2kg of yeast extract, 232kg of lactobacillus plantarum LP, 0.2kg of propylene glycol alginate and 0.1kg of pectin.
The specific manufacturing process comprises the following steps:
s1: heating pure milk to 40deg.C, mixing white sugar, whey protein powder, yeast extract, propylene glycol alginate and pectin, adding, stirring at high speed (stirring rate 10000 r/min), heating to 75deg.C, and stirring for 5min to obtain premixed milk;
s2: cooling the premixed milk in the step S1 to about 60 ℃, homogenizing for 10min under 20MPa to obtain homogenized milk;
s3: sterilizing the homogenized milk in S2 at 92 ℃ for 10min, cooling to 42 ℃ to obtain lactobacillus plantarum LP23, and fermenting at 35 ℃ for 12h;
s4: after fermentation, the treated papaya pulp, the treated oat flakes and the fermented milk are uniformly mixed, filled and refrigerated.
Example 3:
the formula is as follows: 70kg of pure milk, 9kg of papaya pulp, 10kg of oatmeal, 6.45kg of white granulated sugar, 2kg of whey protein powder, 1kg of yeast extract, 231kg of lactobacillus plantarum LP, 0.4kg of propylene glycol alginate and 0.15kg of pectin.
The specific manufacturing process comprises the following steps:
s1: heating pure milk to 40deg.C, mixing white sugar, whey protein powder, yeast extract, propylene glycol alginate and pectin, adding, stirring at high speed (8000 r/min), heating to 75deg.C, and stirring for 5min to obtain premixed milk;
s2: cooling the premixed milk in the step S1 to about 60 ℃, homogenizing for 10min under 20MPa to obtain homogenized milk;
s3: sterilizing the homogenized milk in S2 at 90deg.C for 10min, cooling to 40deg.C, inoculating Lactobacillus plantarum LP23, and fermenting at 35deg.C for 12 hr;
s4: after fermentation, the treated papaya pulp, the treated oat flakes and the fermented milk are uniformly mixed, filled and refrigerated.
Animal experiment:
design of experiment
40 SD female rats with ten weeks of age were selected for the experiment, and the body weight of the experimental rats was about 200-250 g. All rats were free to receive food and water prior to the experiment and were individually kept in clean, well ventilated cages and subjected to light/dark cycles (12 h) at room temperature 25 ℃ to simulate natural conditions. After one week of acclimation, rats were randomly divided into four groups of 10 animals each.
Experimental group 1 is a blank control group, and rats in the group are not subjected to disease modeling; all rats of experimental groups 2, 3, 4 received compound disease modeling for 4 weeks: rats were kept on anger combat for 1 h/day by tail clamping, daily drinking water for rats was replaced with 0.1% ammonia solution at the first day, 20mmol/L sodium deoxycholate solution the second day, and the treated solution was drunk every other day, while starvation and satiety (2 days of overeating followed by 1 day of fasted) was used until disease models were established.
Inoculating lactobacillus required by experiment with LP23 and higher level Lactobacillus plantarum 86066 (university of Dalian medical laboratory) on MRS solid culture medium, transferring MRS liquid culture medium after two passage activation, centrifuging overnight culture solution, re-suspending with sterilized PBS, and preparing 10 9 cfu/mL of bacterial liquid. Lactobacillus plantarum 86066 bacterial liquid (10) 9 cfu/mL of bacterial suspension) was used in the intervention therapy experiment of Experimental group 3, LP23 bacterial liquid (10 9 cfu/mL bacterial suspension) was used for the intervention therapy experiments of trial group 4, the specific groupings are shown in table 3.
TABLE 3 grouping of animal experiments
| Group of | Quantity/quantity only | Grouping situation |
| Experiment group 1 | 10 | Negative control group (disease-free modeling+PBS) |
| |
10 | Positive control group (disease modeling+PBS) |
| Experiment group 3 | 10 | Disease modeling + Lactobacillus plantarum 86066 (10) 9 cfu/mL) |
| |
10 | Disease modeling +Lp23 (10) 9 cfu/mL) |
After the disease model is established successfully, different bacterial suspensions are carried out for 10 weeks to carry out intervention treatment experiments, the bacterial suspensions are infused into the stomach of rats in the experiment groups 3 and 4 at the morning and afternoon respectively, the amount of PBS is infused into the stomach of the other groups at the same amount of 0.5 mL/time. Rats were weighed once every 2 weeks to observe growth, sacrificed after the end of the 10 week experiment, and the gastric mucosa was subjected to histopathological analysis. Rat gastric mucosal tissue extraction using takara rna kit (purchased from takara bio inc.) was performed as follows:
(1) Removing frozen gastric mucosa tissues, and grinding the gastric mucosa tissues into powder in a mortar precooled by liquid nitrogen;
(2) Adding the ground powder into 700 mu L of RL buffer solution in the kit after aggregation;
(3) After the RL is thawed, repeatedly blowing the powder by a pipetting gun until no obvious particles exist, transferring the powder to a 1.5mL RNase-free EP tube after the powder is transparent and viscous;
(4) Centrifuging at 4deg.C for 2min at 12000rmp, collecting supernatant, adding into new 1.5mL RNase-free EP tube, adding 70% ethanol water solution with equal volume concentration, and mixing;
(5) Transferring the mixture to an RNA collection column, centrifuging at 4deg.C and 12000rmp for 2min, and removing filtrate;
(6) Adding RWA buffer solution into 500 mu L of the kit, centrifuging at 4 ℃ and 12000rmp for 30s, and removing filtrate;
(7) Adding 600 μl of RWB buffer in the kit, centrifuging at 4deg.C at 12000rmp for 30s, removing filtrate, and repeating for 1 time;
(8) Collecting the precipitate in a new 2mL centrifuge tube, centrifuging at 4deg.C for 2min at 12000rmp, adding 100 μl RNase-free water, standing at room temperature for 5min, centrifuging for 2min, and eluting RNA;
(9) The eluted RNA samples were stored at-80℃for fluorescent quantitative PCR detection.
Experimental results:
1. dynamic change of rat body weight
The dynamic change of the body weight of rats in each experimental group in the 10-week interventional therapy experiment is shown in fig. 1. Rats in experimental groups 2, 3 and 4 had lower body weight than the rats in experimental group 1 after treatment with disease model without intervention treatment, and the rats were analyzed for their influence on body weight gain after disease modeling, which resulted in slow growth. After probiotic intervention treatment, the growth trend of the experimental groups 3 and 4 is similar to that of the experimental group 1, the growth trend of the experimental group 4 is better, and the result shows that lactobacillus plantarum LP23 possibly promotes the diet of rats and the high-dose group effect is better.
2. Rat gastric mucosal inflammatory factor changes
As shown in fig. 2, the change of gastric mucosal inflammatory factors of rats in different groups is shown in fig. 2, and it can be seen from fig. 2 that the gastric mucosal inflammatory factors IL-1 beta (a in fig. 2) and IL-17 (B in fig. 2) of rats in experimental group 2 are significantly increased (P > 0.01) under the treatment of disease model and untreated condition, while experimental groups 3 and 4 are significantly reduced (P > 0.01) compared with experimental group 2 under the intervention treatment of two probiotics respectively, and in particular, experimental group 4 is substantially maintained at normal level compared with experimental group 1. Experimental results show that the rat has good prevention and treatment effects on inflammatory response caused by stomach deficiency-cold after being subjected to interference treatment by lactobacillus plantarum LP23, and the effect is higher than that of the rat in the industry.
Crowd experiment
1. Study object and method
The tested volunteers are selected from ages 40-75, and are clearly diagnosed as stomach deficiency cold by gastroscopy, and patients with digestive system diseases such as peptic ulcer, pancreatitis, hepatitis, liver cirrhosis, etc. are excluded, except allergic constitution and pregnant or lactating women.
100 test volunteers were selected, of which 72 females and 28 males were randomly divided into 2 groups of 50 volunteers each, wherein the control group was maintained on a normal diet, and the test group was continuously administered once a fruit-flavored fermented milk (example 1) containing lactobacillus plantarum LP23, 150mL, with a bacterial count of 1.0x10, in the morning and evening for 8 weeks 9 CFU/mL. The volunteers were subjected to basic information statistics prior to the experiment, and the Triglyceride (TG), interleukin (IL-6) and tumor necrosis factor α (TNF- α) levels of each group of volunteers were subjected to detection statistical analysis at the 0 th and 8 th weeks of the experiment.
2. Experimental results
The volunteer basic information statistics are shown in Table 4, and the statistics show that the baseline data of the two groups of patients are basically similar and have comparability.
TABLE 4 volunteer basic information
As the experimental time of the two groups of volunteers increases, the content of TG, IL-6 and TNF-alpha in the experimental group is obviously reduced from the data, and the content of TG, IL-6 and TNF-alpha in the group containing lactobacillus plantarum LP23 fermented milk is obviously lower than that in the control group, so that the beneficial effect of the lactobacillus plantarum LP23 fermented milk on triglyceride is proved, the immune function of gastric mucosa is regulated, the inflammation is restrained from repeating, and the treatment effect of the chronic gastritis is improved. The differences were statistically significant, P < 0.05 compared to the control group, as detailed in Table 5.
TABLE 5 Biochemical index results before and after the experiment
While the foregoing describes the embodiments of the present invention, it is not intended to limit the scope of the present invention, and various modifications or variations may be made by those skilled in the art without the need for inventive effort on the basis of the technical solutions of the present invention.
Claims (7)
1. A lactobacillus plantarum LP23 for preventing and assisting in treating stomach deficiency-cold is characterized in that the strain is preserved in China general microbiological culture Collection center (China center for type-8) 22 days in 2022, and the preservation address is No. 3 of North Chen West Lu No.1 in the Korean region of Beijing city, and the preservation number is CGMCC No.25571.
2. The lactobacillus plantarum according to claim 1, characterized in that the 16S rDNA sequence of the lactobacillus plantarum is as follows:
GCTCAGGACGAACGCTGGCGGCGTGCCTAATACATGCAAGTCGAACGAACTCTGGTATTGATTGGTGCTTGCATCATGATTTACATTTGAGTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAATACCGCATAACAACTTGGACCGCATGGTCCGAGCTTGAAAGATGGCTTCGGCTATCACTTTTGGATGGTCCCGCGGCGTATTAGCTAGATGGTGGGGTAACGGCTCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAACTCTGTTGTTAAAGAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCTTCGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGTATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAATGCTAAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATACTATGCAAATCTAAGAGATTAGACGTTCCCTTCGGGGACATGGATACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTATCAGTTGCCAGCATTAAGTTGGGCACTCTGGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAACTCGCGAGAGTAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCAAAGTCGGTGGGGTAACCTTTTAGGAACCAGCCGCCTAAGGTGGGACAGATGATTAGGGTGAAGTCGTAACAAGGTAGCCGTAGGAGAACCTGC, as shown in SEQ ID NO. 1.
3. Use of lactobacillus plantarum according to claim 1 or 2 for the preparation of a health food or medicament for the prevention or adjuvant treatment of stomach deficiency-cold.
4. A health food or medicine for preventing and assisting in treating stomach deficiency-cold, characterized by comprising the lactobacillus plantarum of claim 1 or 2.
5. A fruit-flavored fermented milk comprising the lactobacillus plantarum of claim 1 or 2.
6. The fruit flavored fermented milk of claim 5, wherein the fruit flavored fermented milk is prepared by mixing the following components in parts by weight: 70-75 parts of pure milk, 5-10 parts of papaya pulp, 5-10 parts of oatmeal, 6-8 parts of white granulated sugar, 1-2 parts of whey protein powder, 1-2 parts of yeast extract, 231-2 parts of lactobacillus plantarum LP, 0.2-0.4 part of propylene glycol alginate and 0.05-0.15 part of pectin, wherein the viable count of lactobacillus plantarum LP23 is 1.0X10 8 CFU/ml。
7. The method for preparing fruit granule flavored fermented milk according to claim 5 or 6, which is characterized by comprising the following specific steps:
s1: firstly, heating the formula amount of pure milk to 40 ℃, then uniformly mixing the formula amount of white granulated sugar, whey protein powder, yeast extract, propylene glycol alginate and pectin, adding the mixture, stirring at a high speed, heating to 75 ℃, and stirring for 5 minutes to obtain premixed milk;
s2: cooling the premixed milk in the step S1 to about 60 ℃, homogenizing for 10 minutes under 20MPa to obtain homogenized milk;
s3: sterilizing the homogenized milk in the step S2 at 88-92 ℃ for 10 minutes, cooling to 38-42 ℃ and inoculating lactobacillus plantarum LP23, and then fermenting for 12 hours at 35 ℃ to obtain fermented milk;
s4: after fermentation, uniformly mixing the papaya pulp, the oat flakes and the fermented milk according to the formula, filling and refrigerating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310119349.6A CN116004475B (en) | 2023-02-15 | 2023-02-15 | Lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310119349.6A CN116004475B (en) | 2023-02-15 | 2023-02-15 | Lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116004475A true CN116004475A (en) | 2023-04-25 |
| CN116004475B CN116004475B (en) | 2024-05-03 |
Family
ID=86033646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310119349.6A Active CN116004475B (en) | 2023-02-15 | 2023-02-15 | Lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116004475B (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107619811A (en) * | 2017-11-08 | 2018-01-23 | 光明乳业股份有限公司 | Lactobacillus plantarum CCFM200 bacterial strains and application |
| CN108403725A (en) * | 2018-05-22 | 2018-08-17 | 台州市劢康生物科技有限公司 | Composition for treating digestive tract ulcer and its application |
| CN108570436A (en) * | 2017-12-14 | 2018-09-25 | 浙江大学 | Lactobacillus plantarum ZJUF T17 and its application |
| CN109497135A (en) * | 2018-11-08 | 2019-03-22 | 江南大学 | A kind of acidified milk and preparation method thereof rich in lactobacillus plantarum |
| CN110964665A (en) * | 2019-12-20 | 2020-04-07 | 哈尔滨美华生物技术股份有限公司 | Probiotic composition for post-gastrectomy treatment and preparation method thereof |
| CN111548972A (en) * | 2020-06-03 | 2020-08-18 | 金华银河生物科技有限公司 | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof |
| AU2020101537A4 (en) * | 2020-07-28 | 2020-09-03 | Chongqing University Of Education | A kind of probiotic and application thereof in gastric injury |
| CN111690565A (en) * | 2020-07-02 | 2020-09-22 | 重庆第二师范学院 | Probiotic and application thereof in stomach injury |
| CN111925961A (en) * | 2020-08-13 | 2020-11-13 | 吉林农业大学 | Lactobacillus plantarum Lp2 and application thereof |
| US20210145904A1 (en) * | 2019-11-19 | 2021-05-20 | Southwest University | Use of Lactobacillus Plantarum S58 in Preparation of Product for Alleviating Spicy Food-Induced Damage to Digestive System |
| CN114668783A (en) * | 2022-05-30 | 2022-06-28 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus plantarum strain WKA86 in preparing liver protection/antioxidation/prevention and treatment of alcoholic liver injury medicines |
| CN115651880A (en) * | 2022-12-26 | 2023-01-31 | 四平君乐宝乳业有限公司 | Kefir flora starter culture with 10 strain ratios, K-10 flavored fermented milk and preparation method thereof |
-
2023
- 2023-02-15 CN CN202310119349.6A patent/CN116004475B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107619811A (en) * | 2017-11-08 | 2018-01-23 | 光明乳业股份有限公司 | Lactobacillus plantarum CCFM200 bacterial strains and application |
| CN108570436A (en) * | 2017-12-14 | 2018-09-25 | 浙江大学 | Lactobacillus plantarum ZJUF T17 and its application |
| CN108403725A (en) * | 2018-05-22 | 2018-08-17 | 台州市劢康生物科技有限公司 | Composition for treating digestive tract ulcer and its application |
| CN109497135A (en) * | 2018-11-08 | 2019-03-22 | 江南大学 | A kind of acidified milk and preparation method thereof rich in lactobacillus plantarum |
| US20210145904A1 (en) * | 2019-11-19 | 2021-05-20 | Southwest University | Use of Lactobacillus Plantarum S58 in Preparation of Product for Alleviating Spicy Food-Induced Damage to Digestive System |
| CN110964665A (en) * | 2019-12-20 | 2020-04-07 | 哈尔滨美华生物技术股份有限公司 | Probiotic composition for post-gastrectomy treatment and preparation method thereof |
| CN111548972A (en) * | 2020-06-03 | 2020-08-18 | 金华银河生物科技有限公司 | Lactobacillus plantarum with helicobacter pylori resistance function and application thereof |
| CN111690565A (en) * | 2020-07-02 | 2020-09-22 | 重庆第二师范学院 | Probiotic and application thereof in stomach injury |
| AU2020101537A4 (en) * | 2020-07-28 | 2020-09-03 | Chongqing University Of Education | A kind of probiotic and application thereof in gastric injury |
| CN111925961A (en) * | 2020-08-13 | 2020-11-13 | 吉林农业大学 | Lactobacillus plantarum Lp2 and application thereof |
| CN114668783A (en) * | 2022-05-30 | 2022-06-28 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus plantarum strain WKA86 in preparing liver protection/antioxidation/prevention and treatment of alcoholic liver injury medicines |
| CN115651880A (en) * | 2022-12-26 | 2023-01-31 | 四平君乐宝乳业有限公司 | Kefir flora starter culture with 10 strain ratios, K-10 flavored fermented milk and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| KIM JH等: "Protective Effect of Prunus mume Fermented with Mixed Lactic Acid Bacteria in Dextran Sodium Sulfate-Induced Colitis", 《FOODS》, 29 December 2020 (2020-12-29) * |
| 何方主编: "《神奇美丽的益生菌》", 30 April 2021, 石家庄：河北科学技术出版社 * |
| 常毅主编: "《Hey！该喝牛奶啦！》", 31 January 2021, 北京：中国轻工业出版社, pages: 24 - 27 * |
| 蒋杰等: "乳杆菌改善幽门螺杆菌感染性胃炎的实验研究", 《河南医学研究》, 7 September 2018 (2018-09-07) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116004475B (en) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108004189B (en) | Composite probiotic lactic acid bacteria powder and preparation method and application thereof | |
| CN110835616B (en) | Active substance of lactobacillus paracasei GKS6, composition containing same and application of active substance in promoting longevity | |
| CN107760620B (en) | Lactobacillus plantarum for improving fat-prone constitution and progeny weight and application thereof | |
| CN111996153B (en) | Bifidobacterium breve and application thereof | |
| CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN113755409B (en) | Bifidobacterium longum for relieving insulin resistance and application thereof | |
| CN116286551B (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
| CN114921363A (en) | Composite probiotics for inhibiting fat accumulation and application thereof | |
| CN111493261A (en) | Probiotic solid beverage for relieving or treating constipation symptom | |
| CN113913346A (en) | Lactobacillus paracasei JN-1 and application thereof | |
| CN108904763A (en) | Composition and its preparation method and application containing compound lactobacillus | |
| CN116200305A (en) | Enterococcus durans strain with anti-inflammatory property, culture method and application | |
| CN115120646A (en) | Probiotic composition for balancing intestinal flora and preparation method and application thereof | |
| CN110835615B (en) | Active substance of bifidobacterium lactis GKK2, composition containing same and application of active substance and composition in promoting longevity | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN115337327B (en) | Preparation method and application of probiotic preparation with lipid-lowering, anti-inflammatory and antioxidant functions | |
| CN112514995A (en) | Suckling pig immune milk powder rich in probiotics and prebiotics and preparation method thereof | |
| CN116286458B (en) | Lactobacillus plantarum LZ010 capable of reducing blood pressure and blood fat and application thereof | |
| CN116948876A (en) | Bifidobacterium animalis and application thereof | |
| CN116004475B (en) | Lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof | |
| CN115895966A (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| CN115011513A (en) | Lactic acid bacteria powder for enhancing immunity, regulating intestines and stomach to control fat, losing weight and expelling toxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |